Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
6 days agoLaurus Labs Q2 profit surges 875% to ₹195 crore, revenue up 35%
Laurus Labs, a Hyderabad-based pharmaceutical company, reported a consolidated net profit of ₹195 crore for Q2 FY26, compared to ₹20 crore a year ago — an 875% increase. Revenue rose 35% year-on-year to ₹1,653 crore from ₹1,224 crore. The company credited its growth to strong performance in its CDMO (contract development & manufacturing) business and generics, especially in anti-retrovirals (ARV) and advances in antibody-drug conjugate (ADC) technologies. Management said the results validate its R&D-driven commercial strategy and give confidence for long-term value creation.
Explore:Mutual Fund Tools
positive
6 days agoLaurus Labs Q2 profit surges 875% to ₹195 crore, revenue up 35%
Laurus Labs, a Hyderabad-based pharmaceutical company, reported a consolidated net profit of ₹195 crore for Q2 FY26, compared to ₹20 crore a year ago — an 875% increase. Revenue rose 35% year-on-year to ₹1,653 crore from ₹1,224 crore. The company credited its growth to strong performance in its CDMO (contract development & manufacturing) business and generics, especially in anti-retrovirals (ARV) and advances in antibody-drug conjugate (ADC) technologies. Management said the results validate its R&D-driven commercial strategy and give confidence for long-term value creation.
Explore:Mutual Fund Tools
positive
Laurus Labs Q2 profit surges 875% to ₹195 crore, revenue up 35%
6 days ago
1 min read
83 words
Laurus Labs posted an 875% jump in Q2 profit to ₹195 crore, with 35% revenue growth driven by CDMO and generics business momentum.
Laurus Labs, a Hyderabad-based pharmaceutical company, reported a consolidated net profit of ₹195 crore for Q2 FY26, compared to ₹20 crore a year ago — an 875% increase. Revenue rose 35% year-on-year to ₹1,653 crore from ₹1,224 crore. The company credited its growth to strong performance in its CDMO (contract development & manufacturing) business and generics, especially in anti-retrovirals (ARV) and advances in antibody-drug conjugate (ADC) technologies. Management said the results validate its R&D-driven commercial strategy and give confidence for long-term value creation.
Laurus Labs, a Hyderabad-based pharmaceutical company, reported a consolidated net profit of ₹195 crore for Q2 FY26, compared to ₹20 crore a year ago — an 875% increase. Revenue rose 35% year-on-year to ₹1,653 crore from ₹1,224 crore. The company credited its growth to strong performance in its CDMO (contract development & manufacturing) business and generics, especially in anti-retrovirals (ARV) and advances in antibody-drug conjugate (ADC) technologies. Management said the results validate its R&D-driven commercial strategy and give confidence for long-term value creation.
Companies:
Laurus Labs
Tags:
stocks
india
stocks
india
q2 results
pharma
Laurus Labs
Oct 24, 2025 • 12:52 IST